Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sab Biotherapeutics Inc WT (NQ: SABSW ) 0.0333 UNCHANGED Streaming Delayed Price Updated: 1:30 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.0333 Bid (Size) 0.0332 (13) Ask (Size) 0.0500 (1) Prev. Close 0.0333 Today's Range 0.0333 - 0.0333 52wk Range 0.0100 - 0.1888 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News SAb Biotherapeutics Rebrands as SAB BIO June 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions June 18, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Performance YTD +54.88% +54.88% 1 Month -29.75% -29.75% 3 Month -4.86% -4.86% 6 Month +33.20% +33.20% 1 Year -71.97% -71.97% More News Read More SAB Biotherapeutics Announces Departure of Chief Financial Officer May 30, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics May 21, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates May 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors May 06, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Provides SAB-142 Trial Update April 16, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at INNODIA Annual Meeting April 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference April 04, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment March 25, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the BIO CEO & Investor Conference February 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Executive Leadership Change February 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement January 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split January 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes November 29, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors November 20, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes November 14, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates November 14, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference November 09, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer October 24, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes October 19, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors October 05, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes October 02, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results August 21, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
